Hyperthermia generated with ferucarbotran (Resovist?) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells
详细信息 查看全文
- 作者：Itaru Sato (1) (2)
Masanari Umemura (1)
Kenji Mitsudo (2)
Mitomu Kioi (2)
Hideyuki Nakashima (2)
Toshinori Iwai (2)
Xianfeng Feng (1)
Kayoko Oda (1)
Akiyoshi Miyajima (1)
Ayako Makino (1)
Maki Iwai (1)
Takayuki Fujita (1)
Utako Yokoyama (1)
Satoshi Okumura (3)
Motohiko Sato (4)
Haruki Eguchi (5)
Iwai Tohnai (2)
Yoshihiro Ishikawa (1) - 关键词：Ferucarbotran ; Hyperthermia ; Oral cancer ; Anti ; cancer effect ; Cisplatin ; Resovist?
- 刊名：The Journal of Physiological Sciences
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：64
- 期：3
- 页码：177-183
- 全文大小：
- 参考文献：1. van der Zee J (2002) Heating the patient: a promising approach? Ann Oncol 13(8):1173-184 CrossRef
2. Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T (1986) Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 58(8):1589-595 CrossRef
3. Baba H, Clifton Stephens L, Strebel FR, Siddik ZH, Newman RA, Ohno S, Bull JMC (1991) Protective Effect of ICRF-187 against normal tissue injury induced by Adriamycin in combination with whole body hyperthermia. Cancer Res 51(13):3568-577
4. Ikeda NHO, Kameda H, Ito H, Matsuda T (1994) Experimental study on thermal damage to dog normal brain. Int J Hyperth 10(4):553-61 CrossRef
5. Lin JCWY (1987) Interstitial microwave antennas for thermal therapy. Int J Hyperth 3(1):37-7 CrossRef
6. Stauffer PR, Cetas TC, Fletcher AM, Deyoung DW, Dewhirst MW, Oleson JR, Roemer RB (1984) Observations on the use of ferromagnetic implants for inducing hyperthermia. Biomed Eng, IEEE Trans 31(1):76-0 CrossRef
7. Barry JW, Bookstein JJ, Alksne JF (1981) Ferromagnetic embolization. Experimental evaluation. Radiology 138(2):341-49
8. Rosensweig RE (2002) Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater 252:370-74 CrossRef
9. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13(6):1266-276
10. Hamm BST, Taupitz M, Maibauer R, Speidel A, Huppertz A, Frenzel T, Lawaczeck R, Wolf KJ, Lange L (1994) Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 4(5):659-68 CrossRef
11. Takamatsu S, Matsui O, Gabata T, Kobayashi S, Okuda M, Ougi T, Ikehata Y, Nagano I, Nagae H (2008) Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: feasibility study in rabbits. Radiat Med 26(4):179-87 CrossRef
12. Murase K, Oonoki J, Takata H, Song R, Angraini A, Ausanai P, Matsushita T (2011) Simulation and experimental studies on magnetic hyperthermia with use of superparamagnetic iron oxide nanoparticles. Radiol Phys Technol 4(2):194-02 CrossRef
13. Fram RJ (1992) Cisplatin and platinum analogues: recent advances. Curr Opin Oncol 4(6):1073-079 CrossRef
14. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23(5):460-64 CrossRef
15. Meyer KBMN (1994) Cisplatin nephrotoxicity. Min Electrolyte Metab 20(4):201-13
16. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994-007 CrossRef
17. Los G, Van Vugt MJH, Den Engelse L, Pinedo HM (1993) Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol 46(7):1229-237 CrossRef
18. Los G, van Vugt MJ, Pinedo HM (1994) Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69(2):235-41 CrossRef
19. Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with / cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40(4):1165-168
20. Cohen JD, Robins HI (1987) Hyperthermic enhancement of / cis-Diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res 47(16):4335-337
21. Los GSP, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, Smals O, Gonzalez-Gonzalez D, McVie JG (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27(4):472-77 CrossRef
22. Wang X, Chen Y, Huang C, Wang X, Zhao L, Zhang X, Tang J (2013) Contribution of a 300?kHz alternating magnetic field on magnetic hyperthermia treatment of HepG2 cells. Bioelectromagnetics 34(2):95-03 CrossRef
23. Zhao QLW, Cheng R, Mao L, Arnold RD, Howerth EW, Chen ZG, Platt S (2012) Magnetic nanoparticle-based hyperthermia for head and neck cancer in mouse models. Theranostics 2(1):113-21 CrossRef
24. Atsumi T, Jeyadevan B, Sato Y, Tohji K (2007) Heating efficiency of magnetite particles exposed to AC magnetic field. J Magn Magn Mater 310(2):2841-843 CrossRef
25. Hayashi KNM, Sakamoto W, Yogo T, Miki H, Ozaki S, Abe M, Matsumoto T, Ishimura K (2013) Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics 3(6):366-76 CrossRef
26. Nakao KOY, Akao Y, Ito Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S (2000) The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc 33(1):44-0 CrossRef
27. Shao Y, Aplin AE (2010) Akt3-mediated resistance to apoptosis in B-RAF–targeted melanoma cells. Cancer Res 70(16):6670-681 CrossRef
28. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KSM, Tsai J, Bollag G et al (2010) PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 23(6):820-27 CrossRef
29. Al-Bahlani S, Fraser M, Wong AYC, Sayan BS, Bergeron R, Melino G, Tsang BK (2011) P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30(41):4219-230 CrossRef
30. Kopp AF, Laniado M, Dammann F, Stern W, Gr?new?ller E, Balzer T, Schimpfky C, Claussen CD (1997) MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 204(3):749-56
31. Kusumoto TYM, Baba H, Takahashi I, Kusumoto H, Ohno S, Sugimachi K (1993) Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. Br J Cancer 68(2):259-63 CrossRef
32. Ito A, Honda H, Kobayashi T (2006) Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis-with heat shock protein expression. Cancer Immunol Immunother 55(3):320-28 CrossRef
33. Mitsudo K, Koizumi T, Iida M, Iwai T, Oguri S, Yamamoto N, Itoh Y, Kioi M, Hirota M, Tohnai I (2012) Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases. Int J Radiat Oncol Biol Phys 83(5):639-45 CrossRef
34. Fukumura H, Sato M, Kezuka K, Sato I, Feng X, Okumura S, Fujita T, Yokoyama U, Eguchi H, Ishikawa Y et al (2012) Effect of ascorbic acid on reactive oxygen species production in chemotherapy and hyperthermia in prostate cancer cells. J Physiol Sci 62(3):251-57 CrossRef
35. Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3(1):1351-371 CrossRef
36. Kim H-J, Lee J-H, Kim S-J, Oh GS, Moon H-D, Kwon K-B, Park C, Park BH, Lee H-K, Chung S-Y et al (2010) Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 30(11):3933-946 CrossRef
37. J?ckel M, K?pf-Maier P (1991) Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol 27(6):464-71 CrossRef
38. Pucci B, Kasten M, Giordano A (2000) Cell cycle and apoptosis. Neoplasia 2(4):291-99 CrossRef
39. Aeq B (2004) Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci 61(2):99-02 - 作者单位：Itaru Sato (1) (2)
Masanari Umemura (1)
Kenji Mitsudo (2)
Mitomu Kioi (2)
Hideyuki Nakashima (2)
Toshinori Iwai (2)
Xianfeng Feng (1)
Kayoko Oda (1)
Akiyoshi Miyajima (1)
Ayako Makino (1)
Maki Iwai (1)
Takayuki Fujita (1)
Utako Yokoyama (1)
Satoshi Okumura (3)
Motohiko Sato (4)
Haruki Eguchi (5)
Iwai Tohnai (2)
Yoshihiro Ishikawa (1)
1. Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Yokohama, 236-0004, Japan
2. Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama, 236-0004, Japan
3. Tsurumi University School of Dental Medicine, Tsurumi, 230-8501, Japan
4. Department of Physiology, Aichi Medical University, Nagakute, 480-1195, Aichi, Japan
5. Advanced Applied Science Department, Research Laboratory, IHI Corporation, Yokohama, 235-8501, Japan - ISSN：1880-6562
文摘
Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-5?°C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist?; superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5?°C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.